Stallergenes Greer plc Stallergenes Greer to Report Full Year Financial Results on 22 March 2018
March 15 2018 - 1:31PM
UK Regulatory
TIDM0RB9
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company
specializing in treatments for respiratory allergies, today
announced it will report financial results for the second half and
full fiscal year ended 31 December 2017 on 22 March 2018. The
Company's management will host a live audio webcast of its earnings
conference call at 10:30 am London / 11:30 am Paris / 6:30 am
Boston that same day to discuss the results.
Members of the financial community may access the conference
call through the dial-in information provided on the company's
website, at http://stallergenesgreer.com/financial-calendar-events.
The live audio webcast will be accessible to the general public via
the following link: https://edge.media-server.com/m6/p/ptqhwgnv.
Participants are asked to connect at least 15 minutes prior to the
conference call to register, download and install any necessary
audio software.
ABOUT STALLERGENES GREER PLC
Headquartered in London (UK), Stallergenes Greer plc is a global
healthcare company specializing in the diagnosis and treatment of
allergies through the development and commercialization of allergy
immunotherapy products and services. Stallergenes Greer plc is the
parent company of GREER Laboratories, Inc. (whose registered office
is in the US) and Stallergenes SAS (whose registered office is in
France).
TRADING INFORMATIONName: Stallergenes GreerISIN: GB00BZ21RF93 1
- Ticker: STAGRICB Classification: 4577LEI:
213800CYVZA7GJQEME86Market: Euronext Paris regulated market
Additional information is available at
http://www.stallergenesgreer.com.
This document (including information incorporated by reference
in this document), oral statements made and other information
published by the Company contain statements that are or may be
forward-looking with respect to the financial condition and/or
results of operations and businesses of the Company. These
statements can be identified by the use of forward-looking
terminology such as "believe," "expects," "project," "estimated,"
"forecast," "should," "plan," "may" or the negative of any of
these, or other variations thereof, or comparable terminology
indicating expectations or beliefs concerning future events. These
forward-looking statements include risk and uncertainty because
they relate to events and depend on circumstances that will occur
in the future. Without being exhaustive, such factors include
economic situations and business conditions, including legal and
product evaluation issues, fluctuations in currencies and demand,
and changes in competitive factors. These and other factors are
more fully described in the Company's 2016 annual report published
on 28 April 2017 on the Company's website
www.stallergenesgreer.com. Actual results may differ from those set
forth in the forward-looking statements, due to various factors.
Save as required by applicable law, neither the Company nor any
other person assumes any obligation to update these forward-looking
statements or to notify any person of any such update.
Stallergenes Greer plcCommunication et Relations
investisseursNatacha Gassenbach, +1 (617) 225
8013natacha.gassenbach@stallergenesgreer.comorArnaud de
Cheffontaines, +33 1 47 03 68
10stallergenesgreer@fticonsulting.comorMediasSamuel Rousseau, +33
(0) 6 51 03 51 43samuel.rousseau@havas.com
View source version on businesswire.com:
http://www.businesswire.com/news/home/20180315006106/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
March 15, 2018 13:31 ET (17:31 GMT)
Stallergenes Greer (LSE:0RB9)
Historical Stock Chart
From May 2024 to Jun 2024
Stallergenes Greer (LSE:0RB9)
Historical Stock Chart
From Jun 2023 to Jun 2024